Independent recognition strengthens Vetter’s position as a trusted, high-performing CDMO
• Awards recognize CDMO performance in five categories
• Selection is based on quantitative metrics and verified sponsor feedback from biopharma partners
• Recognition reflects trust placed in Vetter by industry and customers
Ravensburg, March 30, 2026: Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), receives recognition as CDMO of the year in the category “Finished Dose” of the 2026 CDMO Leadership Awards. The award honors the company for exhibiting valued characteristics as a reliable and experienced partner, reaffirming its commitment to offering quality and technical know-how to its customers.
The acknowledgment reinforces Vetter’s strategic role as a
trusted partner for injectable drug development and manufacturing – supporting
customers from early clinical phases through regulatory approval to long-term market
supply. With the increased complexity of biologics and their handling
processes, the pharmaceutical service provider continues to invest in
technologies, capacity, and quality systems to meet evolving global customer
needs. Recent strategic investments in Europe and the United States strengthen
the company’s global footprint, including around €2 billion in planned capacity
expansions through 2035.
“We are committed to supporting our customers every day, and
this award recognizes our ongoing efforts to provide the best customer service
experience possible,” shared Lars Hahn, Vetter’s Senior Vice President Global
Sales Organization. “It underscores our focus on operational excellence,
reliability, and innovation, as well as the devoted hard work of our 7,300
employees to deliver life-enhancing or even life-saving medication to patients
around the world.”
The 15th Annual CDMO Leadership Awards, presented by Outsourced
Pharma and Life Science Connect, were announced during DCAT Week in
New York on March 25, 2026. Award recipients are determined through independent
research conducted by the Tufts Center for the Study of Drug Development,
leveraging real‑world outsourcing performance data and sponsor evaluations from
biopharma companies. CDMOs must meet category‑specific qualifications and
receive a minimum number of qualified customer reviews to be eligible. In 2026,
excellence distinctions were awarded across five key modalities – Biologics, Cell &
Gene Therapy, Small Molecule API, Finished Dose and Fill-Finish. The program is
recognized as one of the most prestigious by industry experts, serving as a
standard for excellence in the life science sector.
“The CDMO
Leadership Awards represent something more meaningful than recognition,” said
Louis Garguilo, Chief Editor of Outsourced Pharma. “They reflect direct
feedback from sponsors and the real-world experiences of companies navigating
today’s development and manufacturing landscape. This year’s finalists and
winners have demonstrated a consistent ability to deliver, adapt, and operate
as trusted partners.”
© Vetter Pharma International GmbH: The Vetter team
is proud to accept the 2026 CDMO Leadership Awards. Those pictured include (from
left) Dr. Sebastian Schuck, Vice President Key Account Management, Lars
Hahn, Senior Vice President Global Sales Organization, Ayse Hizli, Vice
President New Business Development, Michele Cavalheiro, Key Account Manager and
Dr. Claus Feussner, Senior Vice President Development Service.
About Vetter Vetter
is a leading Contract Development and Manufacturing Organization (CDMO) with
headquarters in Ravensburg, Germany, and production facilities in Germany,
Austria, and the US. As a global player, the independent pharmaceutical service
provider is also present in the Asia-Pacific markets of Japan, China, South
Korea and Singapore with sales locations. Around the world renowned pharma and
biotech companies benefit from decades of experience, high quality, modern
technologies, reliability, and commitment of its 7,300 employees. In close
collaboration with its customers, the Vetter team helps enable the supply to
patients all over the world with medicines, many of which are vital. The CDMO
provides support from drug product development through clinical and commercial
filling to a wide range of assembly and packaging services for vials, syringes,
and cartridges. With innovative approaches, Vetter develops prefilled
drug-delivery systems together with its customers to continuously improve
patient safety, comfort, and compliance. Vetter takes responsibility for
sustainable practices and operates as a socially and ethically responsible
corporate citizen. The CDMO is a member of the UN Global Compact and Science
Based Target initiative (SBTi) and received platinum status in the renowned
EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost
& Sullivan Customer Value Leadership Award and the recognition
of Best Managed Company emphasize Vetter’s commitment to sustainable
business. Founded in Ravensburg in 1950, the company remains family-owned to
this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Contact Vetter Pharma International GmbH Markus Kirchner Corporate Spokesperson / Media Relations Eywiesenstrasse 5 88212 Ravensburg Germany Phone: +49 (0)751-3700-3729 E-mail: PRnews@vetter-pharma.com
